Table 1 Patient cohort characteristics from plasma samples collected in benign, no evidence of disease (NED), and metastatic breast cancer (MBC) cohorts
From: Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer
Benign (N = 60) | NED (N = 60) | MBC (N = 60) | |
|---|---|---|---|
Race | |||
Caucasian | 60 (100.0%) | 58 (96.7%) | 59 (98.3%) |
East Asian | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) |
Not Disclosed | 0 (0.0%) | 1 (1.7%) | 1 (1.7%) |
Ethnicity | |||
N-Miss | 4 | 2 | 3 |
Hispanic or Latinx | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) |
Non-Hispanic | 56 (100.0%) | 57 (98.3%) | 57 (100.0%) |
BRCA1/2 mutation | |||
N-Miss | 11 | 8 | 16 |
Carrier | 0 (0.0%) | 0 (0.0%) | 3 (6.8%) |
Non-Carrier | 49 (100%) | 52 (100%) | 41 (93.2%) |
Sex | |||
Male | 0 (0.0%) | 0 (0.0%) | 1 (1.7%) |
Female | 60 (100.0%) | 60 (100.0%) | 59 (98.3%) |
Age | |||
Median (Min-Max) | 62.5 (37–85) | 63 (39–86) | 61.5 (28–72) |
Primary to sample collection (yrs) | |||
Median (Min-Max) | NA | 2.09 (0.75–3.09) | 8.84 (1.08–43.25)a |
Post-sample collection follow-up (yrs) | |||
Median (Min-Max) | 2.4 (0.6–5.2) | 2.7 (1.0–3.5) | |
Primary grade | |||
N-Miss | 60 | 1 | 8 |
1 | 0 | 26 (44.1%) | 6 (11.5%) |
2 | 0 | 29 (49.2%) | 22 (42.3%) |
3 | 0 | 4 (6.8%) | 24 (46.2%) |
Primary stage | |||
N-Miss | 60 | 0 | 1 |
0 | 0 | 1 (1.7%) | |
I | 0 | 43 (71.7%) | 6 (10.0%) |
II | 0 | 16 (26.7%) | 22 (36.7%) |
III | 0 | 1 (1.7%) | 11 (18.3%) |
IV | 0 | 0 (0.0%) | 20 (33.3%)b |
Clinical subtype | |||
N-Miss | 60 | 1 | 0 |
HER2+ | 0 | 3 (5.1%) | 9 (15.3%) |
Luminal A | 0 | 54 (91.5%) | 32 (53.3%) |
Luminal B | 0 | 2 (3.4%) | 16 (26.7%) |
TNBC | 0 | 0 (0.0%) | 3 (5.0%) |
